All Outputs (4)

A propensity-score weighting approach to compare registry and trial populations of patients with psoriasis on biologic therapies (2018)
Presentation / Conference
Yiu, Z., Mason, K., Barker, J., Hampton, P., McElhone, K., Smith, C., …Burden, D. (2018, August). A propensity-score weighting approach to compare registry and trial populations of patients with psoriasis on biologic therapies. Presented at 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague Congress Centre, Prague, Czech Republic

Background: Previous studies using incomplete trial inclusion and exclusion criteria suggest a difference between the reported effectiveness and safety of biologic therapies between randomised clinical trials (RCT) and real-world populations of patie... Read More about A propensity-score weighting approach to compare registry and trial populations of patients with psoriasis on biologic therapies.

The risk of keratinocyte carcinoma (KC) in psoriasis patients receiving biologic therapy compared with conventional systemic therapy: Results from the British Association of Dermatologists Biologic Interventions Register (BADBIR) (2018)
Presentation / Conference
Mason, K. J. (2018, August). The risk of keratinocyte carcinoma (KC) in psoriasis patients receiving biologic therapy compared with conventional systemic therapy: Results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Poster presented at 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague Congress Centre, Prague, Czech Republic

Background: Whether psoriasis patients exposed to biologic therapies have an elevated risk of KC (basal cell carcinoma [BCC] or cutaneous squamous cell carcinoma [cSCC]) remains uncertain. Objectives: To determine whether such patients were at hig... Read More about The risk of keratinocyte carcinoma (KC) in psoriasis patients receiving biologic therapy compared with conventional systemic therapy: Results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Real-world persistence and effectiveness of conventional systemic therapies in the treatment of psoriasis: A systematic review (2018)
Presentation / Conference
Williams, S., Mason, K. J., Yiu, Z., McElhone, K., Warren, R. B., & Griffiths, C. E. (2018, August). Real-world persistence and effectiveness of conventional systemic therapies in the treatment of psoriasis: A systematic review. Paper presented at 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague Congress Centre, Prague, Czech Republic

Background: The effectiveness and persistence of biologic therapies is better understood than more commonly prescribed conventional systemic therapies in clinical practice. Objectives: To evaluate large-scale observational studies investigating th... Read More about Real-world persistence and effectiveness of conventional systemic therapies in the treatment of psoriasis: A systematic review.

THE RISK OF KC IN PSORIASIS PATIENTS RECEIVING BIOLOGICS COMPARED TO CONVENTIONAL SYSTEMIC THERAPIES (2018)
Presentation / Conference
Mason, K. (2018, June). THE RISK OF KC IN PSORIASIS PATIENTS RECEIVING BIOLOGICS COMPARED TO CONVENTIONAL SYSTEMIC THERAPIES. Poster presented at 5th World Psoriasis & Psoriatic Arthritis Conference, Stockholm, Sweden

Introduction: Whether psoriasis patients exposed to biologic therapies have an elevated risk of keratinocyte carcinoma (KC), including basal cell carcinoma (BCC) or cutaneous squamous cell carcinoma (cSCC) remains uncertain. Objective:The aim of t... Read More about THE RISK OF KC IN PSORIASIS PATIENTS RECEIVING BIOLOGICS COMPARED TO CONVENTIONAL SYSTEMIC THERAPIES.